“…The rarity of stable high‐producing cells within these pools necessitated the isolation and screening of hundreds or thousands of clones during a time‐ and resource‐intensive procedure to identify a clonally‐derived cell line with stable and acceptable productivity and product quality attributes, creating a significant bottleneck in the drug development pipeline (Jostock, 2011). Targeted integration platforms, particularly those that employ recombinase‐mediated cassette exchange (RMCE), can accelerate material generation for early product testing by offering unparalleled control over genotype and phenotype (Cain et al, 2013; Carver et al, 2020; Feary et al, 2021; Gödecke et al, 2021; Rajendra et al, 2017; Scarcelli et al, 2017; Shenet al, 2017; Stuible et al, 2018). However, the development of this type of CLD platform first requires knowledge of a precise location within the genome defined as a “hotspot” by its ability to facilitate stable and high transgene expression.…”